A new therapy for the most aggressive type of brain cancer can extend patients' survival while cutting the length of ...

Endocan, a tumor-secreted protein, drives glioblastoma progression and therapy resistance. Targeting it may revolutionize treatment and improve survival.

Cecile Richards, a prominent advocate for women's rights and other progressive causes and former President of Planned ...

Currently, glioblastoma patients primarily receive radiation as their standard treatment, with less than half surviving beyond 12 months after diagnosis. Ropidoxuridine is being developed as a ...

While it may not sound like a major leap, this approach offers one big advantage: killing cancerous cells while doing less damage to surrounding healthy tissue.

Dr. Clark Chen, a neurosurgeon at Rhode Island Hospital, has become the first in the state to utilize GammaTile® Therapy, a bioresorbable ...

The cancer, glioblastoma, is fast-moving and incurable. It's most common in older adults, said Dr. Sujay Vora, a radiation oncologist at the Mayo Clinic, and the median survival time for people ...

The Phase 2 trial design is to initially randomize 40 patients into two different dose levels, with 20 patients receiving ...

Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure.